NASDAQ · XFOR
Healthcare · Biotechnology
$4.29
Down-$0.02 (-0.35%)
Updated Aug 14, 2026, 2:43 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
XFOR closed at $4.29 after 21 trading sessions, up 12.01% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $4.28 | $4.455 | $4.19 | $4.29 | 1.13M |
| Aug 12, 2026 | $4.29 | $4.55 | $4.245 | $4.29 | 1.04M |
| Aug 11, 2026 | $4.19 | $4.425 | $4.13 | $4.28 | 1.08M |
| Aug 10, 2026 | $4.60 | $4.6328 | $4.21 | $4.25 | 658.23K |
| Aug 7, 2026 | $4.26 | $4.82 | $4.215 | $4.64 | 1.6M |
| Aug 6, 2026 | $4.15 | $4.26 | $4.065 | $4.17 | 447.78K |
| Aug 5, 2026 | $4.26 | $4.28 | $4.08 | $4.15 | 372.62K |
| Aug 4, 2026 | $4.10 | $4.33 | $4.10 | $4.29 | 604.73K |
| Aug 3, 2026 | $4.01 | $4.10 | $3.965 | $4.09 | 364.08K |
| Jul 31, 2026 | $4.00 | $4.05 | $3.87 | $3.98 | 415.5K |
| Jul 30, 2026 | $3.96 | $4.23 | $3.96 | $4.00 | 504.6K |
| Jul 29, 2026 | $3.93 | $4.07 | $3.88 | $4.00 | 875.61K |
| Jul 28, 2026 | $3.95 | $3.96 | $3.71 | $3.93 | 861.7K |
| Jul 27, 2026 | $3.86 | $3.995 | $3.83 | $3.94 | 360.03K |
| Jul 24, 2026 | $4.00 | $4.00 | $3.775 | $3.85 | 573.62K |
| Jul 23, 2026 | $3.66 | $4.01 | $3.58 | $3.99 | 579.99K |
| Jul 22, 2026 | $3.67 | $3.765 | $3.56 | $3.695 | 678.17K |
| Jul 21, 2026 | $3.68 | $3.76 | $3.625 | $3.69 | 430.2K |
| Jul 20, 2026 | $3.84 | $3.89 | $3.605 | $3.68 | 729.89K |
| Jul 17, 2026 | $3.73 | $3.85 | $3.70 | $3.82 | 461.94K |
| Jul 16, 2026 | $3.88 | $3.88 | $3.74 | $3.83 | 504.45K |
The latest Smart Investors Daily articles mentioning XFOR.
XFOR research
Company profile and research snapshot.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 10, 2026 | Wells Fargo | Overweight | — |
| Jun 2, 2026 | Leerink Partners | Outperform | — |
| Mar 9, 2026 | Guggenheim | Buy | — |
| Dec 5, 2025 | Stifel | Buy | — |
| Nov 10, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 6, 2026
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of $(3.47) per share
Benzinga · Jul 10, 2026
Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight rating and announces Price Target of $11.
Benzinga · Mar 9, 2026
Benzinga · Mar 9, 2026
Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy rating and announces Price Target of $12.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XFOR.
